Lucentis and Fundoscopy abnormal - a phase IV clinical study of FDA data

Summary:

Fundoscopy abnormal is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Beovu, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Fundoscopy abnormal when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Fundoscopy abnormal?

Fundoscopy abnormal is found to be associated with 33 drugs and 74 conditions by eHealthMe. Check the latest studies of Fundoscopy abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 12 people (0.05%) have Fundoscopy abnormal.

Could Lucentis cause Fundoscopy abnormal?

Among these 12 people:

How long have people been on Lucentis when they have Fundoscopy abnormal? *

What is the gender of people who have Fundoscopy abnormal when taking Lucentis? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Fundoscopy abnormal when taking Lucentis? *

What are other drugs people take besides Lucentis? *

Beovu: 6 people, 50.00%

What are other side effects people have besides Fundoscopy abnormal? *

Visual Acuity Reduced (reduced clearness of vision): 6 people, 50.00%
Retinal Pigment Epithelial Tear (pigment epithelial tear of retina): 6 people, 50.00%
Retinal Haemorrhage (bleeding from retina): 6 people, 50.00%
Eye Inflammation: 6 people, 50.00%
Concomitant Disease Aggravated (advanced due to some of accompanying): 6 people, 50.00%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 6 people, 50.00%
Visual Acuity Reduced Transiently: 3 people, 25.00%
Disease Progression: 3 people, 25.00%
Age-Related Macular Degeneration: 3 people, 25.00%
Retinal Pigment Epitheliopathy (disease of pigment epithelium): 2 people, 16.67%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 9 people, 75.00%
Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 6 people, 50.00%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Fundoscopy abnormal?

- Check whether Fundoscopy abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fundoscopy abnormal:

Fundoscopy abnormal (33 drugs)

Browse all the conditions that are associated with Fundoscopy abnormal:

Fundoscopy abnormal (74 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.